The combination of low or moderate doses of inhaled corticosteroids (ICS) with long-acting β2-agonists (LABA) improves asthma control in adults and reduces exacerbations.1,2 The combination of ICS plus LABA for maintenance therapy has been endorsed in guidelines for the treatment of moderate to severe asthma.3 Recent pharmacogenetic studies demonstrated that the β2-adrenergic receptor (ADRB2) polymorphism modifies bronchodilating response to regular use of short-acting4,5 and long-acting6-8 β2-agonists. 

Individuals homozygous for glycine (Gly) at codon 16 of the ADRB2 gene have greater bronchodilation, measured as the forced expiratory volume in 1 second (FEV1) and maximal mid-expiratory flow (MMEF) to regular treatment of albuterol4,5 and salmeterol.6,8 By contrast, a recent finding in a Korean population9 showed that asthmatic patients with the homozygous Arg/Arg genotype had a significantly greater response of acute bronchodilation to a short-acting β2-agonist. Some studies reported that ADRB2 genetic polymorphisms did not result in significant change of bronchodilating response to short...
were recorded on diary cards. FEV1 was assessed 5 times (at -2, -1, 0, 8, and 24 weeks). Symptoms, nocturnal awakenings, and rescue medication use were recorded 3 times (at 0, 8, and 24 weeks). Viral infection in the proceeding 6 weeks, and an FEV1 of at least 60% of the predicted value, were recruited at Ajou University Hospital, Suwon, and Dankook University Hospital, Cheonan, Korea. All study patients had not been exposed to long acting β2 agonist for 3 months prior to this study, and they provided written informed consent as approved by the local committee on human research.

Outpatients included were required to have been on maintenance therapy with less than 800 µg of inhaled budesonide for at least 3 months and to have a history of at least 1 asthma exacerbation in the previous 12 months. For at least 30 days before enrollment and during the 2-week run-in period, patients took a constant daily dose of 800 µg of budesonide. To be eligible, patients had to have an FEV1 of 60-100% of the predicted value with 12% or more reversibility after 100 µg of salbutamol inhalation compared to baseline, and should have used a short-acting β2-agonist for asthma symptoms on at least 5 of the last 7 days of the run-in. During the 24-week active treatment period, all patients were asked to use combination therapy, while consisted of budesonide 160 µg and formoterol 4.5 µg combined in a device, twice a day as maintenance treatment and for relief as needed. The pretreatment peak expiratory flow meter (PEFR) was assessed twice daily using a Mini-Wright PEFR meter (Clement Clark, Harlow, UK). Daily symptoms, nocturnal awakenings, and rescue medication use were recorded on diary cards. FEV1 was assessed 5 times (at -2, 0, 8, 16, and 24 weeks) by calibrated spirometry. Both PEFR and FEV1 were presented as percent predicted values. An Asthma Control Questionnaire (ACQ; range: 0, absent, to 3 severe) was completed 4 times (at 0, 8, 16, and 24 weeks), and the Asthma Quality of Life Questionnaire (AQLQ; range: 1, severe impairment, to 7, not impaired) validated by the Korean Society of Allergology was recorded 3 times (at 0, 8, and 24 weeks).

**Subjects and study design**

This study was a long-term trial consisting of a 2-week run-in and a 24-week active treatment period. Patients with moderately persistent asthma were recruited, based on the Global Initiative for Asthma (GINA) guidelines. All subjects participated in this study were ethnically Korean. Men and women, aged 18-55 years with a documented history of asthma for at least 6 months, no history of smoking or reported history of viral infection in the proceeding 6 weeks, and an FEV1 of at least 60% of the predicted value, were recruited at Ajou University Hospital, Suwon, and Dankook University Hospital, Cheonan, Korea. All study patients had not been exposed to long acting β2 agonist for 3 months prior to this study, and they provided written informed consent as approved by the local committee on human research.

Subjects and study design

This study was a long-term trial consisting of a 2-week run-in and a 24-week active treatment period. Patients with moderately persistent asthma were recruited, based on the Global Initiative for Asthma (GINA) guidelines. All subjects participated in this study were ethnically Korean. Men and women, aged 18-55 years with a documented history of asthma for at least 6 months, no history of smoking or reported history of viral infection in the proceeding 6 weeks, and an FEV1 of at least 60% of the predicted value, were recruited at Ajou University Hospital, Suwon, and Dankook University Hospital, Cheonan, Korea. All study patients had not been exposed to long acting β2 agonist for 3 months prior to this study, and they provided written informed consent as approved by the local committee on human research.

Outpatients included were required to have been on maintenance therapy with less than 800 µg of inhaled budesonide for at least 3 months and to have a history of at least 1 asthma exacerbation in the previous 12 months. For at least 30 days before enrollment and during the 2-week run-in period, patients took a constant daily dose of 800 µg of budesonide. To be eligible, patients had to have an FEV1 of 60-100% of the predicted value with 12% or more reversibility after 100 µg of salbutamol inhalation compared to baseline, and should have used a short-acting β2-agonist for asthma symptoms on at least 5 of the last 7 days of the run-in. During the 24-week active treatment period, all patients were asked to use combination therapy, while consisted of budesonide 160 µg and formoterol 4.5 µg combined in a device, twice a day as maintenance treatment and for relief as needed. The pretreatment peak expiratory flow meter (PEFR) was assessed twice daily using a Mini-Wright PEFR meter (Clement Clark, Harlow, UK). Daily symptoms, nocturnal awakenings, and rescue medication use were recorded on diary cards. FEV1 was assessed 5 times (at -2, 0, 8, 16, and 24 weeks) by calibrated spirometry. Both PEFR and FEV1 were presented as percent predicted values. An Asthma Control Questionnaire (ACQ; range: 0, absent, to 3 severe) was completed 4 times (at 0, 8, 16, and 24 weeks), and the Asthma Quality of Life Questionnaire (AQLQ; range: 1, severe impairment, to 7, not impaired) validated by the Korean Society of Allergology was recorded 3 times (at 0, 8, and 24 weeks).

**RESULTS**

The clinical and physical characteristics of 43 enrolled patients are shown in Table 1. There were no significant differences in baseline spirometry results between the 2 genotype groups.
with the Arg/Arg genotype group having a mean FEV1 of 77.8% and the Arg/Gly or Gly/Gly genotype group having a mean FEV1 of 73.5%. Mean age and serum total immunoglobulin (Ig) E level were significantly higher in the Arg/Gly or Gly/Gly genotype group (41.5 ± 10.9 vs. 30.8 ± 10.6 years, 2.34 ± 0.5 vs. 1.89 ± 0.57 IU/mL, *p* < 0.05, respectively). However, there were no significant differences in gender, atopy rate, PC20 methacholine, asthma duration, family history of asthma and frequency of exacerbation according to the genotype (all *p* > 0.05).

During the 2-week run-in period, both groups exhibited increase of lung function, but no significant differences were noted between the 2 groups. There was a significant increase of FEV1 during the regularly scheduled combined treatment (*p* < 0.05) (Fig. 1). After 8 weeks of active treatment, treatment effects differed significantly between the genotype groups: patients with an Arg/Arg genotype had significantly higher FEV1% and MMEF% than those with an Arg/Gly or Gly/Gly genotype (*p* < 0.05), whereas no significant differences between the groups were noted for FVC%. This improvement appeared to persist through subsequent 16 weeks, and the mean FEV1 and PEFR levels were then decreased, with statistical significance lost by

---

### Table 1. Comparison of Clinical Characteristics of Study Subjects Stratified by ADRB2 Genotype Group

| Genotype       | Arg/Arg (n = 13) | Arg/Gly or Gly/Gly (n = 30) | *p* value |
|----------------|------------------|-----------------------------|-----------|
| Age (yrs)*     | 30.8 ± 10.6      | 41.5 ± 10.9                 | 0.005     |
| Gender (M / F) | 5 / 8            | 21 / 9                      | 0.089     |
| Atopy (+ / -)  | 5 / 8            | 11 / 19                     | 1.000     |
| Log total IgE (IU / mL)* | 1.89 ± 0.57 | 2.34 ± 0.5                 | 0.021     |
| Baseline FEV1(%)* | 77.8 ± 13.6      | 73.5 ± 12.1                 | 0.316     |
| Asthma duration (yr)* | 9.0 ± 6.5        | 6.2 ± 3.5                   | 0.234     |
| Family history of asthma | 4 / 9         | 7 / 23                      | 0.709     |
| PC20 methacholine (mg / mL)* | 6.75 ± 2.5 | 5.10 ± 2.4                 | 0.646     |
| Number of exacerbation (time / yr)* | 0.50 ± 0.17 | 0.62 ± 0.1                 | 0.602     |
| FVC (%) predicted | 80.5 ± 2.9       | 82.3 ± 2.6                  | 0.698     |
| MMEF (%) predicted | 67.2 ± 7.9       | 52.4 ± 4.7                  | 0.104     |
| Morning PEFR (%) predicted | 88.8 ± 6.3 | 83.8 ± 5.0                  | 0.550     |
| Evening PEFR (%) predicted | 90.7 ± 6.4       | 89.3 ± 7.7                  | 0.900     |
| FEV1 increase after BDT (%)* | 19.7 ± 2.3 | 19.9 ± 1.0                  | 0.930     |

ADRB2, β2-adrenergic receptor; M, male; F, female; FVC, forced vital capacity; MMEF, maximal mid-expiratory flow; PEFR, peak expiratory flow rate; FEV1, forced expiratory volume in 1sec; BDT, bronchodilating test.

*mean ± SD.

Fig. 1. Mean (SD) % predicted value of FEV1 (A), FVC (B) and MMEF (C) during the study period (-2-0 weeks: run-in period; 0-24 weeks: active treatment) for both ADRB2 codon 16 genotype groups (Arg/Arg; Arg/Gly or Gly/Gly). *p* values for Arg/Arg compared with Arg/Gly or Gly/Gly at each time point. FEV1, forced expiratory volume in 1sec; FVC, forced vital capacity; MMEF, maximal mid-expiratory flow; ADRB2, β2-adrenergic receptor.
24 weeks.

There was a significant increase in the quality of life score during the regularly scheduled combined treatment (Fig. 2B). After 24 weeks of active treatment, the treatment effects showed significant differences between the genotype groups; the Arg/Arg group had a significantly higher quality of life than the Arg/Gly or Gly/Gly group ($p < 0.05$), whereas there was a significant decrease in the symptom score during treatment (Fig. 2A). After 24 weeks of active treatment, the treatment effects showed significant differences between the 2 genotypes ($p < 0.05$). However, there was no significant difference in the requirement for rescue medicine according to genotype ($p > 0.05$).

The morning PEFR, measured daily in all subjects, increased after active treatment (Fig. 3A); the regression equations were $y = 89.59 + 5.99 \times \left(1 - 0.97^{\text{time}}\right)$ for the Arg/Arg genotype and $y = 74.91 + 3.13 \times \left(1 - 0.95^{\text{time}}\right)$ for the Arg/Gly or Gly/Gly genotypes. The evening PEFR level was also increased after active treatment, and the equations were $y = 90.78 + 6.49 \times \left(1 - 0.97^{\text{time}}\right)$ for the Arg/Arg genotype and $y = 75.30 + 3.52 \times \left(1 - 0.97^{\text{time}}\right)$ for the Arg/Gly or Gly/Gly genotype (Fig. 3B).

The slopes were calculated using the differential equation of the best-fit line ($y = -b c^{\text{time} \times \ln c}$), the plotted line of each genotype showed different inclination; the slope for the Arg/Arg genotype was steeper than that for the Arg/Gly or Gly/Gly genotype during the active treatment period, however it wasn’t calculated by a statistical tool. The time to reach the plateau morning and evening PEFR levels was longer for the Arg/Arg genotype (87 days for the morning PEFR, 98 days for the evening PEFR) than for the Arg/Gly or Gly/Gly genotype (52 and 81 days, respectively).
**DISCUSSION**

The ADRB2 is a G protein-coupled receptor that mediates the actions of catecholamines in multiple tissues. Nine single-nucleotide polymorphism (SNPs) have been identified in the ADRB2 gene, two of which are more frequent and give rise to amino acid substitutions in the putative extracellular amino-terminus region of the gene; Arg for Gly at codon 16 and Gln for Glu at codon 27. The Gly16 variant has positively been associated with severe asthma and nocturnal asthma. The bronchodilating response to inhaled short- and long-acting β2-agonists shows significant inter-individual variation, depending on the ADRB2 codon 16 genotype, although some studies suggested that the bronchodilating effect caused by rescue treatment with β2-agonists is influenced by haplotypes of the ADRB2 gene. Furthermore, ethnic differences in the pharmacogenetic effects of ADRB2 Arg16Gly polymorphism has been suggested. Choudhry et al. conducted comprehensive family-based pharmacogenetic study of ADRB2 Arg16Gly polymorphism and demonstrated that Arg16 allele was significantly associated with bronchial responsiveness in Puerto Rican, but not in Mexican, subjects with asthma.

Among two common polymorphisms, Arg16Gly and Gly27Gln, of ADRB2 gene, only the Arg16Gly polymorphism was investigated in this study because of very low frequency of minor allele of the Gly27Gln polymorphism in Korean and Japanese population. Study subjects having the Arg16Gly polymorphism were categorized into two groups, such as Arg/Arg and Arg/Gly plus Gly/Gly groups, because of limited number for analysis.

Our results suggest that the ADRB2 Arg16Gly genotype significantly modifies the level of asthma control, as indicated by improvements in lung function, symptom score, and quality of life, in patients who underwent initial regular treatment with a combined ICS (budesonide) and LABA (formoterol). Our findings suggest that patients with the Arg/Arg genotype would receive greater benefit from the regular use of the combined treatment of ICS and LABA as a maintenance treatment than patients with the Arg/Gly or Gly/Gly genotype. Our primary outcome variables were FEV1% and MMEF% predicted values, which are recognized as useful indicators that correlate well with clinical outcomes in asthma. Along with these improvements in lung function, patients in the Arg/Arg group exhibited parallel changes in other outcome variables, such as the symptom and quality of life scores and morning/evening PEFR, all suggesting a clinically relevant genotype-specific effect. Although the Arg/Arg group was younger in age, asthma duration was not different between the 2 groups and lung function parameters were presented as % predicted value, and therefore, the effect of age is likely minimal. Moreover, these findings on the difference in the rates of increase of morning and evening PEFR were replicated, as seen in 2 different genotype-specific equations. Therefore this model could be applied to predict morning/evening PEFR responses with long-term regular use of combination treatment.

The pharmacogenetic response to β2-agonist in this study was not consistent with previous studies in Caucasian subjects that subjects carrying the Gly/Gly genotype at codon 16 of ADRB2 achieved a greater bronchodilation response to a short-acting β2-agonist and a long-acting β2-agonist without ICS, however similar to a previous study in a Korean population that individuals carrying the Arg/Arg genotype achieved a better response to short-acting β2-agonist. This inconsistency result might be due to pharmaco-ethnic differences: ethnic-specific pharmacogenetic difference of ADRB2 Arg16Gly was previously reported between Puerto Rican and Mexican subjects with asthma. There are several polymorphisms in ADRB2 gene, and these functional SNPs can change in drug response to inhaled β2-agonist. This means drug response to inhaled β2-agonists can be altered according to specific haplotype which is constructed by polymorphisms. In the present study, however, we focused on the Arg16Gly because of its important clinical relevance and high minor allele frequency compared to other polymorphisms. Therefore, we couldn’t exclude possibility of any pharmacogenetic effect of other polymorphisms and the pharmaco-ethnic difference observed might be related to other polymorphisms in linkage with the ADRB2 Arg16Gly which we studied.

Different pharmacogenetic effect of ADRB2 polymorphism on the combination therapy (ICS plus LABA) may be explainable by different clinical trial. A recent 6-month double blind randomized study revealed no genotype effect of ADRB2 on the combination therapy in 2,250 asthmatics. These investigators enrolled larger numbers of Arg/Arg homozygous in a longer treatment period than that of Wechsler et al. The size of the study population and design of clinical trial are important for observing pharmacogenetic effect of ADRB2.

In the present study, LABA treatment was combined with ICS, therefore it is quite possible that the differences in response to ICS between genotype groups could account for the observed differences. However, this possibility is quite unlikely, because that all the study subjects used the same regimen of ICS during the 2-week run-in, and showed improvement in both FEV1 and MMEF, with no significant differences observed between genotype groups. Our preliminary study demonstrated that genetic variance of ADRB2 at Arg16Gly could not influence the effect of ICS in a Korean population (unpublished data). Therefore, we propose that the genotype-specific effects found in this study may have been derived from the effects of the long-acting β2-agonist and the ADRB2 Arg16Gly polymorphism, although the effects of ICS on the differential response to LABA according to ADRB2 genotype could not completely be excluded.

Another explanation for the difference between this study and that of Wechsler et al. involves the choice of LABA;
formoterol vs. salmeterol. Cho et al. studied the response to a short-acting $\beta_2$-agonist in a Korean population using albuterol, and found that those carrying the Arg/Arg genotype had better responses to albuterol. This result is similar to our present result, however, dissimilar the finding of long-term albuterol treatment reported by Israel et al. Further investigation is needed to replicate these observations in other Asian populations and confirm these apparent pharmaco-ethnic differences.

In this study, FEV$_1$ and MMEF levels in patients with the Arg/Arg genotype decreased with disappearance of a significant difference in the FEV$_1$ level between the 2 genotype groups at 24 weeks. However, these findings were observed in subjects with the Arg/Gly or Gly/Gly genotype from 16 weeks. Moreover, the morning/evening daily PEFR results demonstrated that the time to reach the plateau of PEFR levels was significantly shorter in the Arg/Gly or Gly/Gly genotype, suggesting that adverse effects such as downregulation of $\beta_2$-adrenergic receptor occur earlier in the Arg/Gly or Gly/Gly type, although the mechanism of this effect remains to be elucidated.

In conclusion, Korean asthmatic patients carrying the Arg/Arg genotype at codon 16 of ADRB2 achieve better asthma control with long-term use of combined treatment with a long-acting $\beta_2$-agonist and ICS, as evidenced by airway function, asthma symptoms, and quality of life. Because of these effects and potential pharmaco-ethnic differences in response, ADRB2 genotyping is likely to play an increasingly important role in the choice of treatment for asthmatic patients.

ACKNOWLEDGEMENTS

This study was supported by grants from the Basic Research Program of the Korea Science and Engineering Foundation (R01-2006-000-10775-0) and the Korea Health 21 R&D Project of the Ministry of Health and Welfare, Republic of Korea (A07001).

REFERENCES

1. O’Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmsqvist M, Zhu Y, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005;171:129-36.
2. Pauwels RA, Lofahl CG, Postma DS, Tattersfield AE, O’Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337:1405-11.
3. Global initiative for asthma (gina) global strategy for asthma management and prevention: National Institutes of Health, National Heart, Lung and Blood Institute; 2006.
4. Israel E, Drazen JM, Liggett SB, Boushey HA, Cherniack RM, Chinchilli VM, et al. The effect of polymorphisms of the $\beta_2$-

adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000;162:75-80.
5. Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004;364:1505-12.
6. Wechsler ME, Lehman E, Lazars SC, Lemanske RF Jr, Boushey HA, Deykin A, et al. beta-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 2006;173:519-26.
7. Palmer CN, Lipworth BJ, Lee S, Ismail T, Macgregor DF, Mukhopadhay S. Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. Thorax 2006;61:940-4.
8. Lee DK, Currie GP, Hall IP, Lima JJ, Lipworth BJ. The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. Br J Clin Pharmacol 2004;57:68-75.
9. Cho SH, Oh SY, Bahn JW, Choi JY, Chang YS, Kim YK, et al. Association between bronchodilating response to short-acting $\beta_2$-agonist and non-synonymous single-nucleotide polymorphisms of $\beta$-adrenoceptor gene. Clin Exp Allergy 2005;35:1162-7.
10. Taylor DR, Epton MJ, Kennedy MA, Smith AD, Iles S, Miller AL, et al. Bronchodilator response in relation to beta2-adrenoceptor haplotype in patients with asthma. Am J Respir Crit Care Med 2005;172:700-3.
11. Hancox RJ, Sears MR, Taylor DR. Polymorphism of the beta2-adrenoceptor and the response to long-term beta2-agonist therapy in asthma. Eur Respir J 1998;11:589-93.
12. Taylor DR, Drazen JM, Heribison GP, Yandava CN, Hancox RJ, Town GI. Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax 2000;55:762-7.
13. Bleecker ER, Yancey SW, Baitinger LA, Edwards LD, Klootsman M, Anderson WH, et al. Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol 2006;118:809-16.
14. Bleecker ER, Postma DS, Lawerence RM, Meyers DA, Ambroze HJ, Goldman M. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 2007;370:2118-25.
15. Choudhry S, Ung N, Avila PC, Ziv E, Nazario S, Casal J, et al. Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. Am J Respir Crit Care Med 2005;171:563-70.
16. Rho HJ, Park MS, Park CW, Yun YY, Park JW, Hong CS, et al. Factors influencing quality of life of asthmatic patients in Korea. J Asthma Allergy Clin Immunol 2000;20:209-21.
17. Liggett SB. Polymorphisms of the beta2-adrenergic receptor and asthma. Am J Respir Crit Care Med 1997;156:S156-62.
18. Holloway JW, Dunbar PR, Riley GA, Sawyer GM, Fitzharris PF, Pearce N, et al. Association of beta2-adrenergic receptor polymorphisms with severe asthma. Clin Exp Allergy 2000;30:1097-103.
19. Contopoulos-Ioannidis DG, Manoli EN, Ioannidis JP. Meta-analysis of the association between bronchodilating response to short-acting beta2-adrenoceptor haplotype in patients with asthma. Eur Respir J 2000;17:129-36.
20. Reihsaus E, Innis M, MacIntyre N, Liggett SB. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Crit Care Med 1997;156:1405-11.
21. Reihnsaus E, Innis M, MacIntyre N, Liggett SB. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Crit Care Med 1997;156:1405-11.
22. Drysdale CM, McGraw DW, Stack CB, Stephens JC, Judson RS,
Nandabalan K, et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A 2000;97:10483-8.

23. Munakata M, Harada Y, Ishida T, Saito J, Nagabukuro A, Matsushita H, et al. Molecular-based haplotype analysis of the beta 2-adrenergic receptor gene (ADRB2) in Japanese asthmatic and non-asthmatic subjects. Allergol Int 2006;55:191-8.

24. Green SA, Turki J, Innis M, Liggett SB. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994;33:9414-9.

25. Green SA, Turki J, Bejarano P, Hall IP, Liggett SB. Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol 1995;13:25-33.

26. Green SA, Rathz DA, Schuster AJ, Liggett SB. The Ile164 beta(2)-adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to G(s). Eur J Pharmacol 2001;421:141-7.

27. Green SA, Cole G, Jacinto M, Innis M, Liggett SB. A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 1993;268:23116-21.